Table 3.

Sensitivity and specificity of each individual molecular test and combinations of tests. Number of evaluable cases and controls varies secondary to variable total DNA quantity and individual test quality control. Only specimens passing quality control measures included.

Molecular test	Endometrial cancer cases (N=38)			Benign endometrium controls (N=27)
	No. evaluated	Sensitivity		No. evaluated	False Positive
		No. (%) positive or present	Exact 95% CI for sensitivity, %		No. (%) positive or present	Exact 95% CI for false positive rate, %
HOXA9 methylation, positive vs. negative	37	14 (37.8%)	(22.5, 55.2)	25	0 (0.0%)	(0.0, 13.7)
RASSF1 methylation, positive vs. negative	35	14 (40.0%)	(23.9, 57.9)	22	0 (0.0%)	(0.0, 15.4)
HTR1B methylation, positive vs. negative	36	14 (38.9%)	(23.1, 56.5)	20	0 (0%)	(0.0, 16.8)
Copy number, present vs. absent	14	5 (35.7%)	(12.8, 64.9)	9	1 (11.1%)	(0.3, 48.3)
Mutation, present vs. absent	20	10 (50.0%)	(27.2, 72.8)	18	3 (16.7%)	(3.6, 41.4)
Methylation (positive for any gene) vs. all 3 tests negative	35	21 (60.0%)	(42.1, 76.1)	18	0 (0%)	(0, 18.5)
Methylation (positive for any gene) OR copy number change present vs. all 4 tests negative or absent	26	23 (88.5%)	(69.9, 97.6)	8	1 (12.5%)	(0.3, 52.7)
Methylation (positive for any gene) OR presence of any gene mutation vs. all 4 tests negative or absent	30	25 (83.3%)	(65.3, 94.4)	17	3 (17.7%)	(3.8, 43.4)
Copy number change present OR presence of any gene mutation vs. both tests negative or absent	18	13 (72.2%)	(46.5, 90.3)	10	4 (40.0%)	(12.2, 73.8)
Methylation (positive for any gene) OR copy number change present OR presence of any gene mutation vs. all 5 tests negative or absent	28	27 (96.4%)	(81.7, 99.9)	10	4 (40.0%)	(12.2, 73.8)
Any positive/present vs. all negative/absent, based on the patients tested for all 5 tests	12	11 (91.7%)	(61.5, 99.8)	7	1 (14.3%)	(0.4, 57.9)